TrialAnnals of the rheumatic diseases2015

MRI assessment of early response to certolizumab pegol in rheumatoid arthritis: a randomised, double-blind, placebo-controlled phase IIIb study applying MRI at weeks 0, 1, 2, 4, 8 and 16.

M Østergaard et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.